Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) dropped 4.7% during trading on Thursday . The stock traded as low as $28.43 and last traded at $28.12. Approximately 115,760 shares were traded during trading, a decline of 77% from the average daily volume of 497,107 shares. The stock had previously closed at $29.51.
Wall Street Analysts Forecast Growth
HROW has been the subject of a number of recent research reports. B. Riley cut their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. HC Wainwright upped their price objective on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th.
Read Our Latest Stock Analysis on HROW
Harrow Price Performance
The stock has a fifty day moving average price of $25.45 and a 200-day moving average price of $30.09. The company has a market cap of $1.09 billion, a PE ratio of -31.48 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.
Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The company had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. On average, equities analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current year.
Hedge Funds Weigh In On Harrow
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC increased its holdings in Harrow by 301.9% during the 3rd quarter. Barclays PLC now owns 52,593 shares of the company's stock valued at $2,365,000 after purchasing an additional 39,506 shares in the last quarter. Calamos Advisors LLC increased its position in Harrow by 35.2% in the fourth quarter. Calamos Advisors LLC now owns 11,913 shares of the company's stock worth $400,000 after purchasing an additional 3,103 shares during the period. Bleakley Financial Group LLC grew its position in shares of Harrow by 63.1% during the 4th quarter. Bleakley Financial Group LLC now owns 8,770 shares of the company's stock worth $294,000 after buying an additional 3,394 shares during the period. Bank of New York Mellon Corp grew its holdings in Harrow by 8.4% during the 4th quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company's stock worth $2,900,000 after acquiring an additional 6,690 shares during the period. Finally, Versor Investments LP acquired a new stake in shares of Harrow during the fourth quarter worth $305,000. Institutional investors own 72.76% of the company's stock.
About Harrow
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
